Table 2 Live and total nucleated cell counts and viability in the E-MSC-treated groups.

From: Angiogenic and Immunomodulatory effects of embryonic stem cell derived mesenchymal stem cells in a murine model of ischemic hindlimb

Variable

Group 3a

Group 4a

Group 5a

Number of live cells (n)

6.35 × 104

1.39 × 105

2.11 × 105

Total cell count (n)

7.06 × 104

1.5 × 105

2.19 × 105

Viabilityb (%)

89.9%

93.0%

96.1%

  1. aGroups 3, 4, and 5 represent cohorts administered E-MSC at low, medium, and high doses, respectively, following induction of ischemia.
  2. bCell viability (%) = (number of live cells/total cell count) × 100; E-MSC, embryonic stem cell–derived mesenchymal stem cell.
Back to article page